Product categories Resources Company Contact For investors For distributors About Devyser We are specialists when it comes to diagnostic kits for complex DNA testing within hereditary diseases, oncology and transplantation. Our products are used to guide targeted cancer therapies, to enable rapid prenatal diagnostics, as well as in post transplant follow-up. Based in Stockholm, Sweden, Devyser was founded in 2004 by three pioneers who envisioned rapid, noninvasive diagnostics based on multiplexed PCR and QF-PCR technology. This has since been applied to the front-end of sequencing workflows in order to streamline protocols. Designed for routine diagnostics We develop DNA tests with the end user in mind. Our focus is on eliminating tedious protocols and streamlining workflows to create tests that are simpler, faster and easier to use in routine diagnostics laboratories. And by simplifying the diagnostic process, we ensure you get cost-effective and reliable results. We have a guiding principle when it comes to developing products that are ideal for routine diagnostics: make the technology simple, reproducible and less prone to user-generated errors. And this is precisely what our customers appreciate about us, which is why routine diagnostic laboratories in more than 60 countries worldwide use our products. Results for life For patients, wait time and result clarity is absolutely critical. You want to be confident that you can provide accurate results quickly. We simplify and streamline complex testing processes to improve your throughput, significantly reduce hands-on time and produce results you can trust. We provide support and customer care through our in-house experts, who understand the day-to-day reality of the diagnostics lab. ‍ Visit our investor relations site © Devyser 2021 By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. More information about cookies Choose cookies Accept All Cookies

Main navigation Reports Media Ownership Governance Top nav Corporate site SV Investor relations. Next event Loading... All events Devyser strives to provide the capital markets, investors and other interested parties with relevant company information and also to be open and impartial in our financial reporting. Press releases November 22, 2021 Devyser intends to list its shares on Nasdaq First North Growth Market in Stockholm September 30, 2021 Pia Gideon new Board member of Devyser February 02, 2021 Devyser completes private placement of SEK 130 million to Swedbank Robur and AP4 January 19, 2021 Devyser receives EUR 750,000 Eurostars grant to develop novel DNA test for early detection of transplant rejection All press releases Key figures Q3 Subscribe Image Sign up Annual report Image Annual report Image Do not hesitate to contact Devyser’s CEO Fredrik Alpsten if you have further questions. Fredrik Alpsten, CEO Fredrik.alpsten@devyser.com +46 706 67 31 06